Which has better earnings & valuation, NBTX or PCVX?

Nanobiotix has higher revenue and earnings than Vaxcyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 53.16 -$27.11M N/A N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is NBTX or PCVX more profitable?

Nanobiotix's return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Vaxcyte N/A -37.56% -33.62%

Does the media prefer NBTX or PCVX?

In the previous week, Vaxcyte had 16 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Vaxcyte and 3 mentions for Nanobiotix. Vaxcyte's average media sentiment score of 0.73 beat Nanobiotix's score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TGTX or NBTX?

TG Therapeutics has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $799.54M 9.55 $447.18M $2.74 18.21 Nanobiotix $36.87M 53.16 -$27.11M N/A N/A

Does the media favor TGTX or NBTX?

In the previous week, TG Therapeutics had 15 more articles in the media than Nanobiotix. MarketBeat recorded 18 mentions for TG Therapeutics and 3 mentions for Nanobiotix. TG Therapeutics' average media sentiment score of 0.34 beat Nanobiotix's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, COGT or NBTX?

Nanobiotix has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Nanobiotix $36.87M 53.16 -$27.11M N/A N/A

Is COGT or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Nanobiotix N/A N/A N/A

Does the media refer more to COGT or NBTX?

In the previous week, Cogent Biosciences had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Cogent Biosciences and 3 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 1.37 beat Nanobiotix's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, NBTX or IBRX?

Nanobiotix has higher earnings, but lower revenue than ImmunityBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 53.16 -$27.11M N/A N/A ImmunityBio $113.29M 71.10 -$351.40M -$0.97 N/A

Is NBTX or IBRX more profitable?

Nanobiotix has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A ImmunityBio -598.55% N/A -51.65%

Does the media refer more to NBTX or IBRX?

In the previous week, ImmunityBio had 12 more articles in the media than Nanobiotix. MarketBeat recorded 15 mentions for ImmunityBio and 3 mentions for Nanobiotix. ImmunityBio's average media sentiment score of 0.34 beat Nanobiotix's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 3 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, RYTM or NBTX?

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rhythm Pharmaceuticals $239.92M 32.24 -$196.54M -$3.11 N/A Nanobiotix $36.87M 53.16 -$27.11M N/A N/A

Does the media favor RYTM or NBTX?

In the previous week, Rhythm Pharmaceuticals had 18 more articles in the media than Nanobiotix. MarketBeat recorded 21 mentions for Rhythm Pharmaceuticals and 3 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 0.54 beat Nanobiotix's score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nanobiotix (NBTX) Competitors

$38.72 +2.54 (+7.02%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$38.66 -0.06 (-0.15%)

As of 08/11/2026 04:10 PM Eastern

Compare

NBTX vs. PCVX, TGTX, COGT, IBRX, and RYTM

Should you buy Nanobiotix stock or one of its competitors? Nanobiotix's main competitors and comparable companies include Vaxcyte (PCVX), TG Therapeutics (TGTX), Cogent Biosciences (COGT), ImmunityBio (IBRX), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nanobiotix compare to Vaxcyte?

Nanobiotix (NASDAQ:NBTX) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Nanobiotix has higher revenue and earnings than Vaxcyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	53.16	-$27.11M	N/A	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

In the previous week, Vaxcyte had 16 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Vaxcyte and 3 mentions for Nanobiotix. Vaxcyte's average media sentiment score of 0.73 beat Nanobiotix's score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix presently has a consensus price target of $37.33, suggesting a potential downside of 3.58%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 45.22%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Nanobiotix's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Vaxcyte	N/A	-37.56%	-33.62%

Nanobiotix has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nanobiotix and Vaxcyte tied by winning 6 of the 12 factors compared between the two stocks.

How does Nanobiotix compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

TG Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 26.25%. Nanobiotix has a consensus price target of $37.33, indicating a potential downside of 3.58%. Given TG Therapeutics' higher possible upside, equities research analysts clearly believe TG Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

TG Therapeutics has a net margin of 55.22% compared to Nanobiotix's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Nanobiotix	N/A	N/A	N/A

TG Therapeutics has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$799.54M	9.55	$447.18M	$2.74	18.21
Nanobiotix	$36.87M	53.16	-$27.11M	N/A	N/A

TG Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, TG Therapeutics had 15 more articles in the media than Nanobiotix. MarketBeat recorded 18 mentions for TG Therapeutics and 3 mentions for Nanobiotix. TG Therapeutics' average media sentiment score of 0.34 beat Nanobiotix's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Nanobiotix on 12 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

38.8% of Nanobiotix shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nanobiotix has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Nanobiotix	$36.87M	53.16	-$27.11M	N/A	N/A

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Nanobiotix	N/A	N/A	N/A

Cogent Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

In the previous week, Cogent Biosciences had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Cogent Biosciences and 3 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 1.37 beat Nanobiotix's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences currently has a consensus target price of $45.90, suggesting a potential upside of 18.60%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 3.58%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cogent Biosciences is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cogent Biosciences beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to ImmunityBio?

Nanobiotix (NASDAQ:NBTX) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Nanobiotix has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nanobiotix presently has a consensus price target of $37.33, suggesting a potential downside of 3.58%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 86.84%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Nanobiotix has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
ImmunityBio	-598.55%	N/A	-51.65%

Nanobiotix has higher earnings, but lower revenue than ImmunityBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	53.16	-$27.11M	N/A	N/A
ImmunityBio	$113.29M	71.10	-$351.40M	-$0.97	N/A

In the previous week, ImmunityBio had 12 more articles in the media than Nanobiotix. MarketBeat recorded 15 mentions for ImmunityBio and 3 mentions for Nanobiotix. ImmunityBio's average media sentiment score of 0.34 beat Nanobiotix's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	3 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmunityBio beats Nanobiotix on 8 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Rhythm Pharmaceuticals presently has a consensus target price of $142.44, suggesting a potential upside of 26.22%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 3.58%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Nanobiotix's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Nanobiotix	N/A	N/A	N/A

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 18 more articles in the media than Nanobiotix. MarketBeat recorded 21 mentions for Rhythm Pharmaceuticals and 3 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 0.54 beat Nanobiotix's score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	32.24	-$196.54M	-$3.11	N/A
Nanobiotix	$36.87M	53.16	-$27.11M	N/A	N/A

Summary

Rhythm Pharmaceuticals beats Nanobiotix on 8 of the 14 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.83B	$3.71B	$7.08B	$12.96B
Dividend Yield	N/A	3.76%	2.57%	10.34%
P/E Ratio	N/A	10.37	268.43	25.05
Price / Sales	53.16	1,283.27	596.77	89.48
Price / Cash	N/A	102.54	72.26	50.42
Price / Book	-19.65	17.98	13.21	6.18
Net Income	-$27.11M	-$13.23M	$3.44B	$347.05M
7 Day Performance	-2.39%	3.20%	2.09%	1.25%
1 Month Performance	-3.37%	-1.17%	-0.23%	-0.64%
1 Year Performance	417.51%	59.41%	70.30%	20.12%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	1.1129 of 5 stars	$38.72 +7.0%	$37.33 -3.6%	+439.7%	$1.83B	$36.87M	N/A	100	Gap Up
PCVX Vaxcyte	2.2197 of 5 stars	$54.70 +2.2%	$86.00 +57.2%	+99.6%	$7.91B	N/A	N/A	160	Earnings Report Analyst Upgrade
TGTX TG Therapeutics	4.1445 of 5 stars	$48.39 +4.8%	$58.67 +21.2%	+89.1%	$7.41B	$616.29M	16.92	290
COGT Cogent Biosciences	1.9331 of 5 stars	$42.73 +10.0%	$45.90 +7.4%	+254.1%	$7.31B	N/A	N/A	80	News Coverage Positive News Earnings Report
IBRX ImmunityBio	2.7634 of 5 stars	$6.94 -3.0%	$14.20 +104.8%	+207.7%	$7.25B	$113.29M	N/A	590

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. PCVX, TGTX, COGT, IBRX, and RYTM

How does Nanobiotix compare to Vaxcyte?

Summary

How does Nanobiotix compare to TG Therapeutics?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Summary

How does Nanobiotix compare to ImmunityBio?

Summary

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. PCVX, TGTX, COGT, IBRX, and RYTM

How does Nanobiotix compare to Vaxcyte?

Which has better earnings & valuation, NBTX or PCVX?

Does the media prefer NBTX or PCVX?

Do analysts rate NBTX or PCVX?

Is NBTX or PCVX more profitable?

Which has more risk and volatility, NBTX or PCVX?

Do institutionals and insiders hold more shares of NBTX or PCVX?

Summary

How does Nanobiotix compare to TG Therapeutics?

Do analysts recommend TGTX or NBTX?

Is TGTX or NBTX more profitable?

Which has better valuation and earnings, TGTX or NBTX?

Which has more risk & volatility, TGTX or NBTX?

Does the media favor TGTX or NBTX?

Do insiders & institutionals hold more shares of TGTX or NBTX?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Do insiders and institutionals have more ownership in COGT or NBTX?

Which has higher valuation and earnings, COGT or NBTX?

Is COGT or NBTX more profitable?

Which has more risk and volatility, COGT or NBTX?

Does the media refer more to COGT or NBTX?

Do analysts recommend COGT or NBTX?

Summary

How does Nanobiotix compare to ImmunityBio?

Which has more volatility and risk, NBTX or IBRX?

Do insiders & institutionals have more ownership in NBTX or IBRX?

Do analysts recommend NBTX or IBRX?

Is NBTX or IBRX more profitable?

Which has preferable earnings & valuation, NBTX or IBRX?

Does the media refer more to NBTX or IBRX?

Summary

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Do analysts recommend RYTM or NBTX?

Is RYTM or NBTX more profitable?

Which has more volatility and risk, RYTM or NBTX?

Does the media favor RYTM or NBTX?

Do insiders & institutionals hold more shares of RYTM or NBTX?

Which has stronger earnings & valuation, RYTM or NBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools